BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/23/2022 3:51:55 PM | Browse: 315 | Download: 824
 |
Received |
|
2021-05-28 23:15 |
|
Peer-Review Started |
|
2021-06-01 02:51 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-14 20:21 |
|
Revised |
|
2021-07-19 05:35 |
|
Second Decision |
|
2022-01-11 03:44 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-01-11 19:51 |
|
Articles in Press |
|
2022-01-11 19:51 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-01-19 08:54 |
|
Publish the Manuscript Online |
|
2022-02-23 15:51 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Samuel J S Rubin, Tatiana Balabanis, John Gubatan and Aida Habtezion |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Stanford Medical Scholars Fellowship Program |
|
|
| Corresponding Author |
Samuel J S Rubin, PhD, Postdoctoral Fellow, Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Alway Building, Room M211, 300 Pasteur Drive, Stanford, CA 94305, United States. yrubin@stanford.edu |
| Key Words |
Inflammatory bowel disease; Immune checkpoint inhibitors; Immunotherapy; Malignancy |
| Core Tip |
Immune checkpoint inhibitor (ICI)-mediated colitis is increasingly recognized as a complication of ICI therapy. The clinical outcomes of ICI therapy on underlying inflammatory bowel disease (IBD) in patients with malignancy is poorly understood. In this retrospective cohort study of IBD patients treated with ICIs for malignancy, we demonstrate that the prevalence of IBD exacerbation following ICI therapy was higher than reported ICI-induced colitis and diarrhea in the general population. ICI use among patients with IBD who had a disease exacerbation was also associated with increased rates of hospitalization. |
| Publish Date |
2022-02-23 15:51 |
| Citation |
Rubin SJS, Balabanis T, Gubatan J, Habtezion A. Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy. World J Clin Cases 2022; 10(6): 1787-1794 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i6/1787.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i6.1787 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
